Clinical trial · Interventional
Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma
Phase I/II Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma
NCT03177668CI-TRIAL-00047342completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to examine tolerability, safety, and pharmacokinetics of YS110 intravenous administration in patients with malignant pleural mesothelioma and to preliminarily examine the anti-tumor effect of YS110.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Pleural Mesothelioma | Pleural Malignant Mesothelioma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| YS110 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- YS110
- description
- Phase 1 part: Administration of 3 different dose cohort Phase 2 part: Administration of recommended dose determined from result of Phase 1 part
- interventionNames
- Drug: YS110
Primary outcomes (7)
- measure
- Status of onset of Dose Limiting Toxicity (DLT)
- timeFrame
- 18 days
- description
- Assessed by number of subjects with DLT of YS110
- measure
- Disease Control Rate (DCR)
- timeFrame
- 6 months
- description
- The proportion of subjects with assessed overall response as Complete Response (CR), Partial Response (PR) or Stable Disease (SD)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with male or female aged ≥ 20 (and aged \< 75 in Phase 1 part) * Patients whose malignant pleural mesothelioma was histologically confirmed * Patients who have advanced pleural mesothelioma that are refractory to existing anti-tumor drugs and who have no other standard therapies which should be prioritized * Patients whose most recent major surgery (except exploratory thoracotomy or laparotomy) or drug or radiation therapy for malignant tumors, if any, was at least 4 weeks ago (at least 12 weeks ago for immunotherapy) at the subject enrollment * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 1 or less Exclusion Criteria: * Patients whose toxicity findings in the previous treatment (antineoplastic agents) have not been yet restored * Patients with tumor lesions in central nervous system confirmed in MRI or CT
References
Publications (0)
Data not yet available
No reference posted for this study.